Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.90 |
| ▸ | CA4 | P22748 | 4/20 | 0.61 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1035225 | 1.00 | — | — | |
| Acetic Acid SCHEMBL8693841 | 0.95 | CA1 (0.82) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL8012154 | 0.95 | CA1 (1.00) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL153505 | 0.95 | CA1 (1.00) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL1331799 | 0.95 | — | — | |
| Acetic Acid SCHEMBL10529780 | 0.95 | CA1 (1.00) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL2343612 | 0.95 | CA1 (1.00) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL1964006 | 0.95 | CA1 (1.00) | CA1CA4FAHD1LMNAFFAR3 | |
| Acetic Acid SCHEMBL2289 | 0.95 | — | — | |
| Acetic Acid SCHEMBL1332333 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122079848-A | Synthesis method of illite-kali plug | — | 2026-05-26 | — | — | CN | claimed |
| CN-117362170-A | Preparation method of cable Ma Lutai intermediate | 四川美大康华康药业有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-114605366-B | Synthesis method and synthesis system for preparing hydroxypropyl pyrantriol by continuous flow | 拓信达(启东)医药生物科技有限公司 | 2023-10-10 | — | — | CN | claimed |
| CN-116444590-A | Preparation method of aminoglycoside compound | 无锡富泽药业有限公司 | 2023-07-18 | — | — | CN | claimed |
| CN-110596067-A | Formaldehyde detection method | 杭州柘大飞秒检测技术有限公司 | 2019-12-20 | — | — | CN | claimed |
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | claimed |
| CN-102741227-B | Aryl benzylamine compounds | NOVARTIS AG | 2014-07-30 | — | — | CN | claimed |
| EP-2531487-B1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-18 | — | — | EP | claimed |
| EP-2531487-A1 | ARYL BENZYLAMINE COMPOUNDS | Novartis AG (CH) | 2012-12-12 | — | — | EP | claimed |
| WO-2011095452-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | claimed |
| CN-122079848-A | Synthesis method of illite-kali plug | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | GENZYME CORP (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4741383-A1 | COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG | Tyligand Bioscience (Shanghai) Limited (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12583839-B2 | PD-L1 antagonist compound | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| EP-4658313-A1 | HSC-SPECIFIC ANTIBODY CONJUGATED LIPID NANOPARTICLES AND USES THEREOF | GENZYME CORPORATION (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| EP-0999205-A1 | AMINOCYCLOALKANE COMPOUNDS | Mitsubishi-Tokyo Pharmaceuticals, Inc. (JP) | 2000-05-10 | — | — | EP | disclosed |
| EP-0976753-A1 | [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5972947-A | ANTICOAGULANT, CARDIOVASCULAR DISORDERS, ANTIINFLAMMATORY AGENTS, OSTEOPOROSIS, ANTITUMOR AGENT | ROCHE DIAGNOSTICS GMBH (DE) | 1999-10-26 | — | — | US | disclosed |
| WO-1999045925-A1 | NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE | RESEARCH TRIANGLE INSTITUTE (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583839-B2 | PD-L1 antagonist compound | CD274, PDCD1LG2, PDCD1 | CA1 1594/4885CA4 2128/4885FAHD1 4389/4885 |
| US-20260137803-A1 | LIPID NANOPARTICLES AND METHODS OF MANUFACTURE AND USE THEREOF | CD2BP2, CD2, CD4 | CA1 1954/4885CA4 3117/4885FAHD1 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.